Ligand Pharmaceuticals Inc
LGND190.840USD
-0.470-0.25%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
3.70BCap. mercado
PérdidaP/E TTM
Más Datos de Ligand Pharmaceuticals Inc Compañía
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. The Company does this by providing financing, licensing its technologies or both. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled several United States Food and Drug Administration (FDA)-approved products, including Gilead's Veklury, Amgen's Kyprolis, Baxter International's Nexterone, Melinta Therapeutics' Baxdela and Sage Therapeutics' Zulresso. Its technologies also include HepDirect, LTP and BEPro Technology Platform, SUREtechnology Platform (owned by Selexis), and Pelican Expression Technology. It has established multiple alliances, licenses and other business relationships with various pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International.
Información de Ligand Pharmaceuticals Inc
Símbolo de cotizaciónLGND
Nombre de la empresaLigand Pharmaceuticals Inc
Fecha de salida a bolsaNov 18, 1992
Director ejecutivoMr. Todd C. Davis
Número de empleados68
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 18
Dirección555 Heritage Drive, Suite 200
CiudadJUPITER
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal33458
Teléfono18585507500
Sitio Webhttps://www.ligand.com/
Símbolo de cotizaciónLGND
Fecha de salida a bolsaNov 18, 1992
Director ejecutivoMr. Todd C. Davis
Ejecutivos de Ligand Pharmaceuticals Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Jason M. Aryeh
Mr. Jason M. Aryeh
Independent Director
Independent Director
127.16K
-7.29%
Dr. John W. Kozarich ,Ph.D.
Dr. John W. Kozarich ,Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
43.90K
-1.05%
Dr. Stephen L. Sabba, M.D.
Dr. Stephen L. Sabba, M.D.
Independent Director
Independent Director
35.05K
+3.57%
Dr. John L. Lamattina, Ph.D.
Dr. John L. Lamattina, Ph.D.
Independent Director
Independent Director
31.98K
+3.93%
Mr. Andrew Reardon
Mr. Andrew Reardon
Chief Legal Officer
Chief Legal Officer
15.72K
-7.77%
Mr. Octavio (Tavo) Espinoza
Mr. Octavio (Tavo) Espinoza
Chief Financial Officer
Chief Financial Officer
10.12K
+2.26%
Dr. Nancy Ryan Gray, Ph.D.
Dr. Nancy Ryan Gray, Ph.D.
Independent Director
Independent Director
9.35K
+14.86%
Mr. Jason Haas
Mr. Jason Haas
Independent Director
Independent Director
6.86K
+21.40%
Dr. Martine Zimmermann, Pharm.D.
Dr. Martine Zimmermann, Pharm.D.
Independent Director
Independent Director
4.17K
-2.68%
Mr. Todd C. Davis
Mr. Todd C. Davis
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Jason M. Aryeh
Mr. Jason M. Aryeh
Independent Director
Independent Director
127.16K
-7.29%
Dr. John W. Kozarich ,Ph.D.
Dr. John W. Kozarich ,Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
43.90K
-1.05%
Dr. Stephen L. Sabba, M.D.
Dr. Stephen L. Sabba, M.D.
Independent Director
Independent Director
35.05K
+3.57%
Dr. John L. Lamattina, Ph.D.
Dr. John L. Lamattina, Ph.D.
Independent Director
Independent Director
31.98K
+3.93%
Mr. Andrew Reardon
Mr. Andrew Reardon
Chief Legal Officer
Chief Legal Officer
15.72K
-7.77%
Mr. Octavio (Tavo) Espinoza
Mr. Octavio (Tavo) Espinoza
Chief Financial Officer
Chief Financial Officer
10.12K
+2.26%
Desglose de ingresos
Divisa: USDActualizado: lun., 6 de oct
Divisa: USDActualizado: lun., 6 de oct
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
Kyprolis
8.80M
18.48%
Captisol
8.29M
17.40%
Filspari
6.58M
13.81%
Qarziba
5.88M
12.36%
Royalties Other
5.43M
11.41%
Otro
12.64M
26.54%
Sin datos
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Kyprolis
8.80M
18.48%
Captisol
8.29M
17.40%
Filspari
6.58M
13.81%
Qarziba
5.88M
12.36%
Royalties Other
5.43M
11.41%
Otro
12.64M
26.54%
Estadísticas de accionistas
Actualizado: dom., 2 de nov
Actualizado: dom., 2 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
13.55%
The Vanguard Group, Inc.
10.64%
Janus Henderson Investors
5.41%
Macquarie Investment Management
4.73%
State Street Investment Management (US)
3.83%
Otro
61.85%
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
13.55%
The Vanguard Group, Inc.
10.64%
Janus Henderson Investors
5.41%
Macquarie Investment Management
4.73%
State Street Investment Management (US)
3.83%
Otro
61.85%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
58.05%
Investment Advisor/Hedge Fund
38.85%
Individual Investor
2.29%
Pension Fund
1.60%
Research Firm
1.26%
Bank and Trust
0.45%
Hedge Fund
0.45%
Sovereign Wealth Fund
0.10%
Venture Capital
0.04%
Participación institucional
Actualizado: dom., 5 de oct
Actualizado: dom., 5 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
538
19.85M
101.27%
-443.72K
2025Q2
535
19.71M
102.13%
-738.05K
2025Q1
554
19.82M
102.82%
-711.89K
2024Q4
546
19.28M
100.16%
-1.51M
2024Q3
543
19.17M
104.83%
-583.22K
2024Q2
527
18.31M
101.74%
-865.78K
2024Q1
520
17.60M
99.35%
-393.03K
2023Q4
527
16.97M
97.29%
-861.76K
2023Q3
515
17.24M
99.38%
-910.17K
2023Q2
526
17.09M
98.94%
-1.02M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
BlackRock Institutional Trust Company, N.A.
2.65M
13.55%
-19.35K
-0.72%
Jun 30, 2025
The Vanguard Group, Inc.
2.08M
10.64%
+33.19K
+1.62%
Jun 30, 2025
Janus Henderson Investors
1.06M
5.41%
+33.19K
+3.23%
Jun 30, 2025
Macquarie Investment Management
926.55K
4.73%
+20.33K
+2.24%
Jun 30, 2025
State Street Investment Management (US)
749.75K
3.83%
+22.63K
+3.11%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
704.52K
3.6%
-40.41K
-5.42%
Jun 30, 2025
Congress Asset Management Company, LLP
647.94K
3.31%
+5.23K
+0.81%
Jun 30, 2025
Chicago Capital, LLC
571.83K
2.92%
+17.31K
+3.12%
Jun 30, 2025
Stephens Investment Management Group, LLC
604.81K
3.09%
-2.41K
-0.40%
Jun 30, 2025
MFS Investment Management
339.74K
1.73%
+61.95K
+22.30%
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: dom., 2 de nov
Actualizado: dom., 2 de nov
Nombre
Proporción
Franklin Genomic Advancements ETF
3.58%
Invesco Pharmaceuticals ETF
3%
Virtus LifeSci Biotech Products ETF
2.58%
SPDR S&P Pharmaceuticals ETF
2.56%
Invesco S&P SmallCap Health Care ETF
2.21%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.92%
Pacer US Small Cap Cash Cows Growth Leaders ETF
1.73%
Invesco Dorsey Wright Healthcare Momentum ETF
1.65%
iShares U.S. Pharmaceuticals ETF
1.28%
OneAscent Small Cap Core ETF
0.97%
Ver más
Franklin Genomic Advancements ETF
Proporción3.58%
Invesco Pharmaceuticals ETF
Proporción3%
Virtus LifeSci Biotech Products ETF
Proporción2.58%
SPDR S&P Pharmaceuticals ETF
Proporción2.56%
Invesco S&P SmallCap Health Care ETF
Proporción2.21%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporción1.92%
Pacer US Small Cap Cash Cows Growth Leaders ETF
Proporción1.73%
Invesco Dorsey Wright Healthcare Momentum ETF
Proporción1.65%
iShares U.S. Pharmaceuticals ETF
Proporción1.28%
OneAscent Small Cap Core ETF
Proporción0.97%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
